These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

948 related articles for article (PubMed ID: 26780747)

  • 1. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.
    Burnett AE; Mahan CE; Vazquez SR; Oertel LB; Garcia DA; Ansell J
    J Thromb Thrombolysis; 2016 Jan; 41(1):206-32. PubMed ID: 26780747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism.
    Witt DM; Clark NP; Kaatz S; Schnurr T; Ansell JE
    J Thromb Thrombolysis; 2016 Jan; 41(1):187-205. PubMed ID: 26780746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D; Pomero F; Benedetti R; Fenoglio L
    Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
    Badreldin H
    J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anticoagulants in the management of venous thromboembolism in women.
    Piovella F; Irina Iosub D
    Thromb Res; 2015 Feb; 135 Suppl 1():S5-7. PubMed ID: 25903537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants.
    Rosovsky R; Merli G
    Tech Vasc Interv Radiol; 2017 Sep; 20(3):141-151. PubMed ID: 29029708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
    Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants.
    Hull RD; Gersh MH
    Curr Med Res Opin; 2015 Feb; 31(2):197-210. PubMed ID: 25299352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of dabigatran etexilate for the treatment of venous thrombosis.
    Feuring M; van Ryn J
    Expert Opin Drug Discov; 2016 Jul; 11(7):717-31. PubMed ID: 27159158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of cancer-associated venous thromboembolism - a case-based practical approach.
    Voigtlaender M; Langer F
    Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.
    Bertoletti L; Ollier E; Duvillard C; Delavenne X; Beyens MN; De Magalhaes E; Bellet F; Basset T; Mismetti P; Laporte S
    Pharmacol Res; 2017 Apr; 118():33-42. PubMed ID: 27350265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
    Abdel-Razeq H; Finianos A; Taher AT
    Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.